Advanced search
1 file | 5.51 MB Add to list

Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro μ-opioid receptor assays and in vivo behavioral studies in mice

Author
Organization
Project
Abstract
2-Benzylbenzimidazole derivatives or 'nitazenes' are increasingly present on the recreational drug market. Here, we report the synthesis and pharmacological characterization of 15 structurally diverse nitazenes that might be predicted to emerge or grow in popularity. This work expands the existing knowledge about 2-benzylbenzimidazole structure-activity relationships (SARs), while also helping stakeholders (e.g., forensic toxicologists, clinicians, policymakers) in their risk assessment and preparedness for the potential next generation of nitazenes. In vitro mu- opioid receptor (MOR) affinity was determined via competition radioligand (3[H]DAMGO) binding assays in rat brain tissue. MOR activation (potency and efficacy) was studied by means of a cell-based beta- arrestin 2 recruitment assay. For seven nitazenes, including etonitazene, opioid-like pharmacodynamic effects (antinociception, locomotor activity, body temperature changes) were evaluated after subcutaneous administration in male C57BL/6 J mice. The results showed that all nitazenes bound to MOR with nanomolar affinities, and the functional potency of several of them was comparable to or exceeded that of fentanyl. In vivo, dose-dependent effects were observed for antinociception, locomotor activity, and body temperature changes in mice. SAR insights included the high opioid-like activity of methionitazene, iso-butonitazene, sec-butonitazene, and the etonitazene analogues 1-ethyl-pyrrolidinylmethyl N-desalkyl etonitazene and ethylene etonitazene. The most potent analogue of the panel across all functional assays was alpha'-methyl etonitazene. Taken together, through critical pharmacological evaluation, this work provides a framework for strengthened preparedness and risk assessments of current and future nitazenes that have the potential to cause harm to users.
Keywords
UND VERWANDTE HETEROCYCLEN, Nitazene, New synthetic opioids, In vitro and in vivo pharmacology, Structure-activity relationships, 2-Benzylbenzimidazoles, mu-Opioid receptor

Downloads

  • 1-s2.0-S1043661824004481-main.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 5.51 MB

Citation

Please use this url to cite or link to this publication:

MLA
Vandeputte, Marthe, et al. “Characterization of Novel Nitazene Recreational Drugs: Insights into Their Risk Potential from in Vitro μ-Opioid Receptor Assays and in Vivo Behavioral Studies in Mice.” PHARMACOLOGICAL RESEARCH, vol. 210, 2024, doi:10.1016/j.phrs.2024.107503.
APA
Vandeputte, M., Glatfelter, G. C., Walther, D., Layle, N. K., Germaine, D. M. St., Ujváry, I., … Stove, C. (2024). Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro μ-opioid receptor assays and in vivo behavioral studies in mice. PHARMACOLOGICAL RESEARCH, 210. https://doi.org/10.1016/j.phrs.2024.107503
Chicago author-date
Vandeputte, Marthe, Grant C. Glatfelter, Donna Walther, Nathan K. Layle, Danielle M. St. Germaine, István Ujváry, Donna M. Iula, Michael H. Baumann, and Christophe Stove. 2024. “Characterization of Novel Nitazene Recreational Drugs: Insights into Their Risk Potential from in Vitro μ-Opioid Receptor Assays and in Vivo Behavioral Studies in Mice.” PHARMACOLOGICAL RESEARCH 210. https://doi.org/10.1016/j.phrs.2024.107503.
Chicago author-date (all authors)
Vandeputte, Marthe, Grant C. Glatfelter, Donna Walther, Nathan K. Layle, Danielle M. St. Germaine, István Ujváry, Donna M. Iula, Michael H. Baumann, and Christophe Stove. 2024. “Characterization of Novel Nitazene Recreational Drugs: Insights into Their Risk Potential from in Vitro μ-Opioid Receptor Assays and in Vivo Behavioral Studies in Mice.” PHARMACOLOGICAL RESEARCH 210. doi:10.1016/j.phrs.2024.107503.
Vancouver
1.
Vandeputte M, Glatfelter GC, Walther D, Layle NK, Germaine DMSt, Ujváry I, et al. Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro μ-opioid receptor assays and in vivo behavioral studies in mice. PHARMACOLOGICAL RESEARCH. 2024;210.
IEEE
[1]
M. Vandeputte et al., “Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro μ-opioid receptor assays and in vivo behavioral studies in mice,” PHARMACOLOGICAL RESEARCH, vol. 210, 2024.
@article{01JKARSRWTKTAM1JMJRNKQJD0D,
  abstract     = {{2-Benzylbenzimidazole derivatives or 'nitazenes' are increasingly present on the recreational drug market. Here, we report the synthesis and pharmacological characterization of 15 structurally diverse nitazenes that might be predicted to emerge or grow in popularity. This work expands the existing knowledge about 2-benzylbenzimidazole structure-activity relationships (SARs), while also helping stakeholders (e.g., forensic toxicologists, clinicians, policymakers) in their risk assessment and preparedness for the potential next generation of nitazenes. In vitro mu- opioid receptor (MOR) affinity was determined via competition radioligand (3[H]DAMGO) binding assays in rat brain tissue. MOR activation (potency and efficacy) was studied by means of a cell-based beta- arrestin 2 recruitment assay. For seven nitazenes, including etonitazene, opioid-like pharmacodynamic effects (antinociception, locomotor activity, body temperature changes) were evaluated after subcutaneous administration in male C57BL/6 J mice. The results showed that all nitazenes bound to MOR with nanomolar affinities, and the functional potency of several of them was comparable to or exceeded that of fentanyl. In vivo, dose-dependent effects were observed for antinociception, locomotor activity, and body temperature changes in mice. SAR insights included the high opioid-like activity of methionitazene, iso-butonitazene, sec-butonitazene, and the etonitazene analogues 1-ethyl-pyrrolidinylmethyl N-desalkyl etonitazene and ethylene etonitazene. The most potent analogue of the panel across all functional assays was alpha'-methyl etonitazene. Taken together, through critical pharmacological evaluation, this work provides a framework for strengthened preparedness and risk assessments of current and future nitazenes that have the potential to cause harm to users.}},
  articleno    = {{107503}},
  author       = {{Vandeputte, Marthe and Glatfelter, Grant C. and Walther, Donna and Layle, Nathan K. and Germaine, Danielle M. St. and Ujváry, István and Iula, Donna M. and Baumann, Michael H. and Stove, Christophe}},
  issn         = {{1043-6618}},
  journal      = {{PHARMACOLOGICAL RESEARCH}},
  keywords     = {{UND VERWANDTE HETEROCYCLEN,Nitazene,New synthetic opioids,In vitro and in vivo pharmacology,Structure-activity relationships,2-Benzylbenzimidazoles,mu-Opioid receptor}},
  language     = {{eng}},
  pages        = {{14}},
  title        = {{Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro μ-opioid receptor assays and in vivo behavioral studies in mice}},
  url          = {{http://doi.org/10.1016/j.phrs.2024.107503}},
  volume       = {{210}},
  year         = {{2024}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: